MONTREAL--(BUSINESS WIRE)--AngioChem, a biotechnology company discovering and developing drugs that are uniquely capable of crossing the blood-brain barrier, announced today that its first patent has been granted by the U.S. Patent and Trademark office. U.S. Patent Number 7,557,182 is entitled “Aprotinin polypeptides for transporting a compound across the blood-brain barrier” and covers the Angiopep-2 EPiC peptide and conjugates, including ANG1005. ANG1005 is AngioChem’s lead drug candidate currently being evaluated in two distinct Phase I/II clinical trials for cancers of the brain, and positive clinical data were recently presented on ANG1005 at the American Association for Cancer Research (AACR) annual meeting in April 2009.
